IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	₩16,270.00	-3.56%	31,190
11/09/26	₩16,870.00	-0.65%	21,644
10/09/26	₩16,980.00	-1.34%	31,277
09/09/26	₩17,210.00	-1.77%	25,257
08/09/26	₩17,520.00	+0.98%	39,029

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 14/09/2026			5-day change	1st Jan Change
16,270.00 ^KRW	-3.56%		-10.90%	-71.66%

07-23	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
12-22	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI

Market Cap	244B 181M 157M 148M 134M 252M 17.34B 254M 1.77B 681M 8.82B 682M 666M 28.06B	P/E 2024 *	-	P/E 2025	-77.1x
Enterprise Value	224B 166M 144M 136M 123M 231M 15.88B 233M 1.62B 624M 8.08B 624M 610M 25.7B	EV / Sales 2024 *	-	EV / Sales 2025	365,559,272x
Free-Float	78.73%	Yield 2024 *	-	Yield 2025	-

07-23	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
12-22	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI
31/10/25	IntoCell Inc. and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies	CI
30/10/25	Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding Its Payload-Linker Platform and Bioconjugate Capabilities	CI

1 day	-3.56%
1 week	-10.90%
Current month	-14.19%
1 month	-25.37%
3 months	-27.20%
6 months	-66.21%
Current year	-71.66%

IntoCell, Inc. Share Price

Stocks

A287840

KR7287840003

Biotechnology & Medical Research

Valuation: IntoCell, Inc.

Chart: IntoCell, Inc.

Latest news: IntoCell, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: IntoCell, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	16,130	18,100
1 month	16,130	22,925
Current year	13,050	63,500
1 year	13,050	74,900
3 years	13,050	74,900
5 years	13,050	74,900
10 years	13,050	74,900

Manager	Title	Age	Since
Tae-Kyo Park CEO	Chief Executive Officer	66	31/03/2015
Young-Seok Seo DFI	Director of Finance/CFO	69	31/05/2019
Yo-Seop Yu CTO	Chief Tech/Sci/R&D Officer	58	31/03/2021

Director	Title	Age	Since
Tae-Kyo Park BRD	Director/Board Member	66	31/03/2015
Yo-Seop Yu BRD	Director/Board Member	58	31/03/2021
Gyeong-Se Min BRD	Director/Board Member	65	31/03/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
15/07/25	Tae-Kyo Park	Buy	Founder	10,000	0.0674%
15/07/25	Tae-Kyo Park	Buy	Founder	26,000	0.1751%
28/05/25	Jae-Hee Choi	Free		40,400	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTOCELL, INC.	-3.56%	-10.90%	-57.85%	-	189M
LONZA GROUP AG	+0.56%	-5.82%	-2.45%	+9.99%	45.48B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+524.38%	43.68B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+22.65%	43.09B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+76.85%	39.4B
CELLTRION, INC.	+0.34%	-4.94%	+9.34%	+40.23%	31.91B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+111.39%	16.4B
EUROFINS SCIENTIFIC SE	+2.07%	-0.77%	+13.07%	+32.89%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+34.13%	13.28B
Average	+0.37%	-3.39%	+50.41%	+106.56%	26.5B
Weighted average by Cap.	+0.94%	-3.26%	+75.90%	+126.85%

	2024	2025
Net sales	2.91K 2.16 1.87 1.76 1.6 3 206.14 3.02 21.04 8.1 104.87 8.1 7.92 333.57	2.3K 1.71 1.48 1.4 1.26 2.37 163.15 2.39 16.65 6.41 83 6.41 6.27 263.99
Net income	-9.91B -7.36M -6.37M -6.02M -5.45M -10.22M -703M -10.3M -71.78M -27.64M -358M -27.65M -27.02M -1.14B	-10.6B -7.87M -6.82M -6.44M -5.83M -10.93M -752M -11.02M -76.78M -29.56M -383M -29.57M -28.91M -1.22B
Net Debt	-2.15B -1.59M -1.38M -1.3M -1.18M -2.21M -152M -2.23M -15.54M -5.98M -77.47M -5.99M -5.85M -246M	-20.59B -15.27M -13.24M -12.5M -11.32M -21.22M -1.46B -21.39M -149M -57.39M -743M -57.41M -56.12M -2.36B